Sarepta Therapeutics, a biopharmaceutical company focused on rare genetic diseases, has named Michael Severino as its new CEO. Severino, who previously led Tessera Therapeutics, steps into the role as Sarepta navigates challenges in gene therapy development and regulatory landscapes. His appointment follows a period of strategic reevaluation for the company, which has faced scrutiny over its Duchenne muscular dystrophy treatments and pipeline progress.
Sarepta Therapeutics has appointed Michael Severino as its new chief executive officer, effective immediately. Severino succeeds Doug Ingram, who stepped down after leading the company since 2017. The announcement comes as Sarepta faces heightened scrutiny over its gene therapy pipeline and commercial performance, particularly in treatments for Duchenne muscular dystrophy.
Severino brings extensive experience in biotechnology leadership, having served as CEO of Tessera Therapeutics, a gene writing company, since 2021. Prior to Tessera, he held executive roles at AbbVie, including vice chairman and president, where he oversaw global research and development and commercial operations. His background in immunology and neurology may align with Sarepta’s focus on rare genetic disorders.
DISCUSSION (0)